Dyne Therapeutics, INC. (DYN) — 8-K Filings

8-K Filings (20)

• Dyne Therapeutics Announces Executive and Director Changes — Dec 23, 2025 Risk: low
  Dyne Therapeutics, Inc. announced on December 22, 2025, changes in its executive and director roles. The company filed a Form 8-K detailing the departure of cer
• Dyne Therapeutics Files 8-K with Material Agreement — Dec 10, 2025 Risk: medium
  On December 9, 2025, Dyne Therapeutics, Inc. entered into a material definitive agreement. The company also reported other events and filed financial statements
• 8-K Filing — Dec 8, 2025
• Dyne Therapeutics Reports Officer and Director Changes — Oct 2, 2025 Risk: medium
  Dyne Therapeutics, Inc. filed an 8-K on October 2, 2025, reporting changes effective October 1, 2025. The filing indicates a departure of directors or certain o
• Dyne Therapeutics Files 8-K — Aug 4, 2025 Risk: low
  Dyne Therapeutics, Inc. filed an 8-K on August 4, 2025, to report on other events and a Regulation FD disclosure. The filing does not contain specific financial
• Dyne Therapeutics Files 8-K with Material Agreement Details — Jul 1, 2025 Risk: medium
  On June 30, 2025, Dyne Therapeutics, Inc. filed an 8-K report detailing a material definitive agreement. The filing also included other events and financial sta
• Dyne Therapeutics Enters Material Definitive Agreement — Jun 30, 2025 Risk: medium
  On June 27, 2025, Dyne Therapeutics, Inc. entered into a material definitive agreement. This filing also indicates the creation of a direct financial obligation
• Dyne Therapeutics Files 8-K for Regulatory Updates — Jun 17, 2025 Risk: low
  Dyne Therapeutics, Inc. filed an 8-K on June 17, 2025, to report on other events and provide financial statements and exhibits. The filing does not detail speci
• Dyne Therapeutics Files 8-K on Security Holder Votes — Jun 5, 2025 Risk: low
  Dyne Therapeutics, Inc. filed an 8-K on May 30, 2025, to report on the submission of matters to a vote of its security holders. The filing does not detail the s
• Dyne Therapeutics Files 8-K on Officer/Director Changes — Mar 20, 2025 Risk: medium
  Dyne Therapeutics, Inc. filed an 8-K on March 20, 2025, reporting events as of March 17, 2025. The filing primarily concerns the departure of directors or certa
• Dyne Therapeutics Files Current Report — Jan 10, 2025 Risk: low
  Dyne Therapeutics, Inc. filed an 8-K on January 10, 2025, reporting its status as a Delaware corporation with its principal executive offices in Waltham, Massac
• Dyne Therapeutics Files 8-K — Nov 12, 2024 Risk: low
  Dyne Therapeutics, Inc. filed an 8-K on November 12, 2024, to report other events and financial statements/exhibits. The filing does not contain specific detail
• 8-K Filing — Sep 3, 2024
• Dyne Therapeutics Files 8-K on Shareholder Vote Matters — May 24, 2024 Risk: low
  Dyne Therapeutics, Inc. filed an 8-K on May 24, 2024, reporting on matters submitted to a vote of its security holders on May 22, 2024. The filing details the c
• Dyne Therapeutics Files 8-K: Material Agreement & Other Events — May 22, 2024 Risk: medium
  On May 21, 2024, Dyne Therapeutics, Inc. entered into a material definitive agreement. The company also reported other events and filed financial statements and
• Dyne Therapeutics Partners with Pfizer for DMD Drug — May 20, 2024 Risk: medium
  Dyne Therapeutics, Inc. announced on May 20, 2024, that it has entered into a clinical collaboration with Pfizer Inc. to evaluate Dyne's novel antibody-oligonuc
• Dyne Therapeutics Appoints New CEO, Dr. Kristin Yarema — Mar 25, 2024 Risk: medium
  Dyne Therapeutics, Inc. announced on March 21, 2024, the appointment of Dr. Kristin Yarema as Chief Executive Officer and a member of the Board of Directors, ef
• Dyne Therapeutics Files 8-K on Material Definitive Agreement — Jan 5, 2024
  Dyne Therapeutics, Inc. filed an 8-K on January 4, 2024, to report an "Entry into a Material Definitive Agreement" and "Other Events." While the filing indicate
• Dyne Therapeutics Files 8-K, Confirms Emerging Growth Status — Jan 4, 2024
  Dyne Therapeutics, Inc. filed an 8-K on January 4, 2024, to report an "Other Event." This filing indicates that Dyne Therapeutics is an "emerging growth company
• Dyne Therapeutics Files Routine 8-K, Confirms Nasdaq Listing — Jan 3, 2024
  Dyne Therapeutics, Inc. filed an 8-K on January 3, 2024, to report a routine administrative update, specifically regarding its common stock, which trades under

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX